06998 嘉和生物－Ｂ
按盘价 
1.490 +0.090 (+6.429%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -37.865% | -29.338% | -26.886% | -140.590% | -60.690% |
| 股东资金回报率 (%) | -45.088% | -34.021% | -30.230% | -175.330% | -100.151% |
| 资本运用回报率 (%) | -55.396% | -39.371% | -33.935% | -91.048% | -140.077% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | N/A | 93.830% | N/A | 74.872% | 26.666% |
| 未计利息、税项、折旧及摊销前利润率 (%) | N/A | -4575.960% | N/A | -27611.432% | -3680.773% |
| 税前边际利润率 (%) | N/A | -4597.163% | N/A | -29390.282% | -4015.929% |
| 纯利率 (%) | N/A | -4583.317% | N/A | -29301.152% | -4004.003% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 5.407 X | 6.606 X | 7.620 X | 12.469 X | 0.967 X |
| 速动比率 (X) | 5.383 X | 6.424 X | 7.462 X | 12.342 X | 0.897 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 17.706% | 14.651% | 12.915% | 9.412% | 69.235% |
| 总债项 / 总资产比率 (%) | 0.495% | 1.352% | 2.005% | 0.869% | 5.699% |
| 净债项 / 总资产比率 (%) | -80.057% | -73.761% | -74.864% | -81.117% | -28.896% |
| 总债项 / 股东资金比率 (%) | 0.602% | 1.586% | 2.305% | 0.960% | 19.071% |
| 长期债项 / 股东资金比率 (%) | 0.330% | 1.211% | 0.807% | 0.495% | 13.403% |
| 净债项 / 股东资金比率 (%) | -97.435% | -86.554% | -86.067% | -89.630% | -96.699% |
| 净现金 / (债项) ($) | 11.58亿 | 15.60亿 | 21.43亿 | 28.99亿 | 2.12亿 |
| 每股净现金 / (债项) ($) | 2.282 | 3.088 | 4.265 | 5.903 | -- |
| 总债项 / 资本运用比率 (%) | 0.588% | 1.541% | 2.252% | 0.934% | 11.205% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | -- | 18019.229日 | -- | 3988.426日 | 964.013日 |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | N/A | 2999.177日 | N/A | 3446.408日 | 1878.760日 |
| 备注： | 实时报价更新时间为22/11/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -125,695,000 |
| 增长率 | -54.218% |
| 每股盈利/(亏损) | RMB -0.250 |
| 每股账面资产净值 (¥) | RMB 2.066 |